When VC Doesn’t Fit

Venture capital has become the default mental model for funding a life science company. For many founders, that default is so deeply embedded that a failed VC raise gets interpreted as a failed business. But those are not the same thing. In life sciences, plenty of strong companies are not poor-quality ventures; they are simply a poor fit for the return expectations, risk profile, and timing assumptions built into institutional venture capital.

The wrong capital strategy can do real damage. A company with a service model, early revenue, or a platform business may spend years trying to squeeze itself into an investor category built around binary therapeutic outcomes and very large exits. In the process, founders can waste time, distort strategy, and accept financing terms that do not match how the business generates cash. The better question is not whether a company is “venture-backable” in the abstract. It is whether the capital instrument matches the company.

The dominance of venture capital in biotech storytelling makes the model look more universal than it is. Founders see the headline IPO, the major M&A deal, or the massive Series A round and naturally assume that institutional equity is the benchmark path for ambitious life science companies. In practice, that path was designed around a narrower profile: a company with a high-risk asset, a very large potential market, a clear regulatory value inflection, and a plausible path to outsized returns within a fund’s timeline. This profile is ideal for some industries (I’m thinking tech, but others match, too), and it works well for some life science companies. For example, a therapeutics company built around a novel asset, a meaningful unmet need, and credible downstream acquirers may fit venture logic even if the science is risky. The return profile can still make sense if investors believe the upside is large enough and the company can reach a decisive value-creation milestone before capital needs become overwhelming.

However, a large share of life science businesses do not fit this profile. Some are services businesses with attractive margins but limited venture-scale upside. Some are diagnostics, tools, or specialized manufacturing companies that can become durable and profitable without ever becoming unicorns. Some are platform companies with hybrid revenue streams that are too operationally grounded for classic biotech investors and too technically complex for generalist software investors. When those businesses are rejected by VC firms, founders often hear “not investable.” Instead, the market may simply be saying “not investable with this instrument.”

So, how should we handle these companies that operationally solid but not designed for unicorn-style equity returns? They may have customers, contracts, or early product revenue. They may have better line-of-sight to cash flow than to a ten-times valuation jump tied to a single event. They certainly need capital, not because the business is speculative, but because growth requires inventory, staffing, validation work, quality systems, or modest infrastructure expansion.

A structure sometimes described as a “3x3 term sheet” helps illustrate the gap. The basic idea is simple: investors target a capped return, often around three times invested capital over roughly three years. The returns are typically paid through a revenue-share, royalty-backed, or similarly structured repayment mechanism. This structure creates a financing path for companies that are solid businesses that don’t fit either classic VC or business bank debt. It’s appealing for founders and some types of investors because both have practical protections and measurable returns in the deal.

Similar kinds of structures can make sense for capital-light life science companies that are already near commercialization or have recurring revenue visibility. Examples might include a specialized CRO, a service lab, a diagnostics business with active test volume, a real-world data or clinical workflow software company, or a platform business with dependable fee-for-service revenue. These businesses are unlikely to achieve a venture-scale exit, but their business models, when executed well, support structured repayment from operating performance. The same model breaks quickly for companies without a near-term cash flow engine. A de novo therapeutics company with years of preclinical and clinical development ahead of it has huge capital needs with no revenue to support repayment. A hardware or diagnostics company facing significant capital expenditures, regulatory clearance, and reimbursement uncertainty may also struggle under a repayment structure that assumes near-term operational performance. In cases like these, alternate capital can become expensive bridge financing in disguise.

The important lesson is there is more than one capital structure available to early-stage companies. The capital markets are also slowly getting better at recognizing businesses that sit between pure venture and traditional lending, so we may expect more options in the future. I advise founders to develop an early capital strategy, consider all their options, and be prepared to adapt when circumstances change.

Once founders move beyond the assumption that all growth capital must look like equity, the financing landscape becomes more practical. The relevant categories are not buzzwords; they are mechanisms tied to different kinds of underwriting.

These remain foundational for many life science companies. SBIR and STTR awards are the most familiar examples, but they are not the whole story. BARDA, ARPA-H, disease foundations, and mission-driven public or quasi-public funding sources can support technology development without immediate dilution. Contracts can be especially powerful when the company has a product or capability that aligns with a government or institutional need. The tradeoff, of course, is that this capital is usually slow, scoped, and administratively demanding. It can fund progress, but it rarely substitutes for a complete company-building strategy.

This category can work when a company has a believable path to recurring or near-term revenue. Instead of giving up ownership, the company commits a defined share of future revenue or a capped repayment stream. These structures reward predictability. They are often a poor fit for a company whose only plausible repayment source is the next equity round.

This category can provide useful extensions for a company that already has institutional backing. These facilities can extend runway with less dilution than a new priced round, but they are usually not available on charisma alone. Lenders want evidence that equity investors are already committed and that the company has enough institutional support to manage risk.

These are often underappreciated by founders who have been taught to think in financing categories alone. Platform deals, option-to-license structures, fee-for-service partnerships, co-development arrangements, and milestone-bearing collaborations can all function as strategic financing. In some cases, they are better than financing because they validate both the science and the market.

This category includes capped revenue-share notes, convertible notes, net-asset-value (NAV) loans, and a multitude of other options. Hybrids can be attractive for companies that are too early for bank debt but too operational for pure venture. The discipline they impose can also be healthy, but only if the repayment assumptions are grounded in actual business performance rather than optimism.

In all instances, it’s important to find a funding partner who understands and values how this investment structure fits your company and their portfolio. Founders need due diligence, too; a clear capital strategy demands it.

Not every life science company should pursue alternate capital, and treating these structures as universally founder-friendly is a mistake. The best candidates usually share three traits: they are relatively capital light compared with drug development, they have visibility into revenue or partnership cash flows, and they can grow meaningfully without betting everything on a single binary event. Good fits often include service-based platforms, specialized CROs, clinical operations or real-world evidence software, digital health businesses with actual customers, diagnostics or lab tools with early sales traction, and specialized manufacturing businesses. These companies may still be innovative and scientifically sophisticated, but investors are underwriting some version of operating cash flow rather than waiting for a distant exit event.

One illustrative example is a drug substance manufacturing firm using it’s starter facility to fulfill contracts for reference standards while building toward a broader expansion strategy. That type of company may be able to use contract revenue as proof of demand and as a partial support for growth financing. If state or regional economic development partners can also help the company access a lower-cost line of credit, the capital stack becomes more creative and more resilient. Importantly, those opportunities do not always come from the usual investor circles.

Poor fits are just as important to understand. A single-asset therapeutics company with no credible revenue for five to seven years should be extremely cautious with any financing structure that depends on repayment before a major equity event. The same is true for capital-intensive hardware or diagnostics businesses that still face regulatory, manufacturing, and reimbursement bottlenecks before commercial traction is possible. If the business cannot realistically repay from operations, then alternate capital may simply layer obligation on top of uncertainty. This is where founders can get into trouble. Investors in these structures are generally underwriting cash flow, not scientific elegance. If the company does not have a real or near-term cash flow proxy, the structure can become painful precisely when the business is least able to absorb it.

The headline benefit of non-equity or hybrid capital is obvious: less dilution, more founder control, and sometimes faster access to money than a traditional venture round. What can be underestimated are the downstream signaling and encumbrance effects. Every financing instrument tells the next investor something about how the company has been underwritten. Revenue claims, redemption features, synthetic royalties, or stacked repayment obligations may look manageable in the moment, but future institutional investors may see them as friction or unresolvable cap table issue. A later VC may worry that the company is already economically overcommitted. A strategic partner may worry that part of the program has been effectively pre-sold. A lender may see a crowded capital stack and decide the risk is no longer attractive. This does not mean founders should avoid alternate capital. It means they should price in the full cost, including what happens in the next round, not just the current one. Capital strategy should be planned across the life of the company. A structure that solves today’s cash problem but overcomplicates a future partnership or financing can still be the wrong deal.

Founders need a decision framework that begins with honesty rather than hope. Start with the cash-flow timeline. Is there a credible path to recurring revenue, partnership payments, contracts, or royalty-like income within the next three to four years? If not, many repayment-oriented structures should move down the list immediately. Next, map the financing instrument to the business model. What exactly is the investor underwriting? Product sales, service contracts, licensing payments, future milestones, or the expectation of another equity round? If the answer is vague, the structure is probably carrying more risk than it first appears. Then pressure-test the terms. Capped returns sound simple until subordination provisions, default triggers, cash sweep mechanics, exclusivity terms, revenue definitions, or milestone covenants enter the picture. A founder does not need to become a structured finance expert, but they do need to understand where control, flexibility, and future fundraising options may narrow.

Outside expertise matters here. The right support team may include life science-focused deal counsel, reimbursement or regulatory advisors when market timing affects repayment logic, and a fractional CFO or venture advisor who has seen these structures play out over time. General startup advice is often not enough, especially in sectors where development timelines and commercialization pathways are so specific. Founders should also widen the search for informed perspective. Regional life science associations, sector-specific accelerators, non-dilutive funding specialists, experienced operators, and economic development partners can all surface options that a standard venture network misses. One of the most useful questions in these conversations is not “will you invest?” but “what capital structures have actually worked for companies like this one?”

The strongest financing plans in life sciences are rarely binary. They are layered. A company might start with grants or translational funding, add contract or partnership revenue, use a structured credit or revenue-share product to bridge a growth phase, and raise equity only when the business truly matches equity return math. Another company may never need traditional VC at all, and that may be a sign of discipline rather than limitation. That reframing is important for founders who have internalized venture as a status marker. Raising well does not mean raising the most visible money. It means choosing capital that matches the company’s technical risk, commercialization path, and timing of cash generation. When VC does not fit, the company is not necessarily broken. It may simply be telling the truth about what kind of business it is. Founders who understand that early can stop performing for the wrong capital market and start building a financing strategy that supports the company they are trying to create. Go look for the funders with portfolios that match your capital strategy.

Thanks for reading Thinking Kat! If you found this issue valuable, please pass it to someone else who would benefit.

Share Thinking Kat